Background: Ovarian cancer is the fifth leading cause of cancer-related deaths among women worldwide. Unfortunately, early detection tests are relatively lacking. Diagnosis in the late stages of the disease carries a poor prognosis. Objective: To evaluate the relationship between miR-196a-2 rs11614913 polymorphism and ovarian cancer risk and prognosis in Egyptian females. Methods: In this case-control study, the participants were classified into 2 groups. Group A is the control group which included 50 healthy females. Group B included 50 patients newly diagnosed with ovarian carcinoma confirmed by histopathological analysis. Immunohistochemistry for P53 and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for miR-196a-2 genotypes detection were performed. Results: There was a statistically significant difference among ovarian cancer cases and controls regarding genotypes (P = 0.003). However, the distribution of the T and C alleles in both studied groups showed no significant difference (P = 0.17). There was a statistically significant increase of CA 125 levels among CT and CC genotypes carriers of ovarian cancer cases (p = 0.04). Besides, there was a statistically significant correlation between miR-196a-2 polymorphism and each of tumor grade (P <0.001), p53 immunohistochemical expression (P= 0.002), and Figo classification (P <0.001). Conclusion:There was a statistically significant increase of CA 125 levels among C allele carriers of ovarian cancer cases. Besides, there was a statistically significant association between the miR-196a-2 polymorphism and each of tumor grade, p53 immunohistochemical expression, and Figo classification. So, miR-196a-2 polymorphism can be a possible prognostic factor in ovarian cancer.
Background: Essential hypertension (EH) is the most well-known cardiovascular illness. It is estimated that (30% -40%) of blood pressure (BP) is caused by genetic factor. This work aims to investigate the relation between 11 beta hydroxysteroid dehydrogenase type 1 ) 11β-HSD1 ( gene polymorphism and EH in patients attending Zagazig University Hospitals. Methods: Thirty-one patients having EH and the control group of thirty-one apparently healthy individuals. 11β-HSD1 gene polymorphism (rs45487298) was analyzed by restriction fragment length polymorphism reaction. Results: we found that A allele was significantly higher in hypertension (HTN) group and Subjects carrying A allele had a higher incidence to have HTN (OR = 2.5, 95 % CI = 1.04-5.8 and P = 0.04). Levels of TG, and total cholesterol, were significantly higher and levels of HDL cholesterol were significantly lower in A/A than in wt\wt genotype. Also, A allele and triglycerides are independent risk factor for EH development.Conclusions: there was a significant relation between 11β-HSD1 gene polymorphism and EH.
Background Chronic hepatitis C (CHC) is a silent viral infection; however, elevated mortality and morbidity rates are noted in Egypt due to its adverse effects. The augmented incidence of diabetes in patients with viral C infection may be owing to glucose intolerance, high BMI, senility, and inherited factors. Purpose of the study Little information is available about the connection between interleukin-28B (IL-28B) genotype in disease progression among CHC patients with diabetes. Thus, we aimed to assess the association between IL-28B genotype (rs12979860) in CHC with type 2 diabetes mellitus (T2DM) versus those without diabetes in disease progression among Egyptian patients. Results CC genotype was significantly lower in diabetics than in non-diabetics (13.7% vs. 36.3%). While (CT/TT) were significantly higher in diabetics than in non-diabetics (CT 58.8% vs. 43.7%), (TT 27.5% vs. 20%) (p = 0.03) and likewise alleles (p = 0.04). Multivariate logistic regression analysis was significant with viral load p < 0.001, alanine aminotransferase (ALT) p < 0.001, genotype CC versus TT p = 0.04 & T2DM p = 0.03. Conclusion CC genotype might be used as a protective factor and TT genotype as a risk factor in disease progression among CHC patients with T2DM. Additionally, viral load, ALT & T2DM might interplay as predictors of disease severity. Detecting the genetic factors can be helpful in predicting and preventing the complications of diabetes associated with the hepatitis C virus (HCV).
Background and study aim: Helicobacter pylori (H. pylori) is a common organism in developing countries, it causes gastric disorders and cancer. Pathogenesis of these disorders involve cytokine gene polymorphisms that affect cytokine levels and clinical diseases. The aim of the study is to identify the relationship of IL-1β-511, IL-10-519 and TNF-α-308 polymorphisms to the risk of H. pylori infection and occurrence of gastric disorders. Subjects and methods: IL-1β-511, IL-10-519 and TNF-α-308 polymorphisms were assessed using polymerase chain reaction (PCR) restriction fragment length polymorphism technique (RFLP) in 356 subjects classified according to H. pylori infection and gastric disorders. Results: Carriers of T allele of IL-1β-511 and IL-10-519 had increased risk of H. pylori infection (OR:1.95, 95% CI:1.4-2.7, P<0.001 & OR:1.8, 95% CI:1.4-2.5, P<0.001; respectively). The IL-1β-511 and IL-10-519 T allele was associated with gastritis, peptic ulcer (PU) & gastric cancer (GC) (P< 0.001). Simultaneous occurrence of either IL-1β-511 TT or IL-10-519 TT genotypes with H. pylori significantly augmented the risk for different gastric diseases (gastritis; P=0.005 & 0.002, PU; P=0.01&0.02 and GC; P=0.02&0.01; respectively). While, the copresence of TNF-α-308 GA+ AA genotypes and H. pylori was related to gastritis only. Conclusion: This study revealed a significant association of the IL-1β-511C/T and IL-10-819C/T but not TNF-α-308 G/A polymorphisms with risk of Helicobacter pylori infection and different gastric diseases in Egyptian patients..
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.